Interestingly, combined PI3K and PARP inhibition have also provided more efficient responses in BRCA1-deficient breast cancer cells [55] and dual ATR and BCR inhibition has also been proven to be synergistic in ATM-defective CLL cells [56]. Here, BRCA1 is linked to breast cancer.